Get the Stockscreener App
7.27
2.68%
0.19
Pre-market:
7.01
-0.26
-3.58%
Puma Biotechnology Inc stock is traded at $7.27, with a volume of 223.92K.
It is up +2.68% in the last 24 hours and down -3.58% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$7.08
Open:
$7.15
24h Volume:
223.92K
Relative Volume:
0.66
Market Cap:
$370.04M
Revenue:
$228.37M
Net Income/Loss:
$31.11M
P/E Ratio:
11.90
EPS:
0.6108
Net Cash Flow:
$41.73M
1W Performance:
+6.75%
1M Performance:
-3.58%
6M Performance:
+43.96%
1Y Performance:
+124.73%
1-Day Range:
$7.05
$7.295
1-Week Range:
$6.77
$7.295
52-Week Range:
$3.03
$7.8983
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
7.27 | 360.37M | 228.37M | 31.11M | 41.73M | 0.6108 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
PBYI Stock Price, Quote & Chart | PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) - ChartMill
PBYI Stock Inches Higher: The Quiet Puma Biotechnology Signal Investors Are Watching - Bez Kabli
PBYI SEC FilingsPuma Biotechnology Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Puma Biotechnology's (NASDAQ:PBYI) Soft Earnings Are Actually Better Than They Appear - 富途牛牛
PBYI Q1 earnings & sales beat estimates, 2026 guidance raised - MSN
Puma forecasts $202M-$206M in 2026 NERLYNX net product revenue while planning alisertib dose escalation and new Lung2 trial - MSN
Puma Biotechnology Reveal Hidden Strength Amid Rising Market Focus - Kalkine Media
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings - simplywall.st
Puma Biotechnology IncCommon Stock (NQ: PBYI - FinancialContent
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
TradingKey - TradingKey
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00 - Yahoo Finance
Puma Biotechnology Reports Q1 2026 Revenue and Positive Outlook - HarianBasis.co
Puma Biotechnology Q1 2026 Financial Results: Revenue, Net Loss, and Key Risk Disclosures - Minichart
PBYI Puma Biotechnology beats Q1 earnings estimates by 69.8%, shares rise 3.17% on positive outlook.Stability Report - newser.com
Puma Biotechnology Q1 Earnings Call Highlights - sharewise.com
Puma (PBYI) Q1 2026 Earnings Call Transcript - The Globe and Mail
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised - The Globe and Mail
Puma Biotechnology, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PBYI) 2026-05-08 - Seeking Alpha
Puma Biotechnology, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Puma Biotechnology Reports First Quarter 2026 Financial Results - BioSpace
PUMA BIOTECHNOLOGY INC (NASDAQ:PBYI) Beats Q1 Estimates, Raises Full-Year Guidance - ChartMill
Earnings call transcript: Puma Biotech Q1 2026 misses EPS, revenue forecasts - Investing.com
Earnings call transcript: Puma Biotech Q1 2026 misses EPS, revenue forecasts By Investing.com - Investing.com South Africa
PBYI: Q1 2026 NERLYNX revenue dropped 3% year-over-year, with 78% of patients on reduced doses - TradingView
Puma Biotechnology : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Puma Biotech: Q1 Earnings Snapshot - KTVB
MSN Money - MSN
Puma Biotechnology Q1 revenue falls on weaker NERLYNX sales; raises 2026 outlook - TradingView
Puma Biotechnology (NASDAQ: PBYI) swings to Q1 2026 loss - Stock Titan
Puma Biotechnology (NASDAQ: PBYI) raises 2026 guidance and eliminates debt - Stock Titan
Cancer drug NERLYNX demand pushes Puma to raise 2026 outlook - Stock Titan
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)May 6, 2026 - BioSpace
Puma Biotechnology reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Six new Puma hires get stock awards covering 59,750 shares - Stock Titan
Puma Biotechnology (PBYI) to Release Quarterly Earnings on Thursday - MarketBeat
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Puma Biotechnology | 10-Q: Q2 2025 Earnings Report - Moomoo
CEO warrant extension and pay vote at Puma Biotechnology (NASDAQ: PBYI) meeting - Stock Titan
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Puma Biotechnology Inc Stock (PBYI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| AUERBACH ALAN H | President and CEO |
Jan 06 '26 |
Sale |
5.84 |
16,938 |
98,986 |
7,163,963 |
| HUNT DOUGLAS M | See Remarks |
Jan 07 '26 |
Sale |
5.88 |
5,014 |
29,477 |
155,907 |
| HUNT DOUGLAS M | See Remarks |
Jan 06 '26 |
Sale |
5.84 |
3,973 |
23,218 |
160,921 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jan 07 '26 |
Sale |
5.88 |
6,405 |
37,655 |
193,284 |
| NOUGUES MAXIMO F | Chief Financial Officer |
Jan 06 '26 |
Sale |
5.84 |
4,540 |
26,532 |
199,689 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):